Amplified Host Defense by Toll-Like Receptor-Mediated Downregulation of the Glucocorticoid-Induced Leucine Zipper (GILZ) in Macrophages
Overview
Authors
Affiliations
Activation of toll-like receptors (TLRs) plays a pivotal role in the host defense against bacteria and results in the activation of NF-κB-mediated transcription of proinflammatory mediators. Glucocorticoid-induced leucine zipper (GILZ) is an anti-inflammatory mediator, which inhibits NF-κB activity in macrophages. Thus, we aimed to investigate the regulation and role of GILZ expression in primary human and murine macrophages upon TLR activation. Treatment with TLR agonists, e.g., PamCSK (TLR1/2) or LPS (TLR4) rapidly decreased GILZ mRNA and protein levels. In consequence, GILZ downregulation led to enhanced induction of pro-inflammatory mediators, increased phagocytic activity, and a higher capacity to kill intracellular bacteria ( enterica serovar ), as shown in GILZ knockout macrophages. Treatment with the TLR3 ligand polyinosinic: polycytidylic acid [Poly(I:C)] did not affect mRNA levels, although GILZ protein expression was decreased. This effect was paralleled by sensitization toward TLR1/2- and TLR4-agonists. A bioinformatics approach implicated more than 250 miRNAs as potential GILZ regulators. Microarray analysis revealed that the expression of several potentially GILZ-targeting miRNAs was increased after Poly(I:C) treatment in primary human macrophages. We tested the ability of 11 of these miRNAs to target GILZ by luciferase reporter gene assays. Within this small set, four miRNAs (hsa-miR-34b,-222,-320d,-484) were confirmed as GILZ regulators, suggesting that GILZ downregulation upon TLR3 activation is a consequence of the synergistic actions of multiple miRNAs. In summary, our data show that GILZ downregulation promotes macrophage activation. GILZ downregulation occurs both via MyD88-dependent and -independent mechanisms and can involve decreased mRNA or protein stability and an attenuated translation.
Legroux T, Schymik H, Gasparoni G, Mohammadi S, Walter J, Libert C Front Immunol. 2024; 15:1396827.
PMID: 38855102 PMC: 11157436. DOI: 10.3389/fimmu.2024.1396827.
Rusev S, Thon P, Rahmel T, Ziehe D, Marko B, Nowak H Int J Mol Sci. 2024; 25(7).
PMID: 38612684 PMC: 11011808. DOI: 10.3390/ijms25073871.
Paglialunga M, Flamini S, Contini R, Febo M, Ricci E, Ronchetti S Cells. 2023; 12(18).
PMID: 37759516 PMC: 10528232. DOI: 10.3390/cells12182294.
Al-Fityan S, Diesel B, Fischer T, Ampofo E, Schomisch A, Mashayekhi V Pharmaceutics. 2023; 15(7).
PMID: 37514081 PMC: 10385046. DOI: 10.3390/pharmaceutics15071895.
Grossi L, Zaidan I, Souza J, Carvalho A, Sanches R, Cardoso C Cells. 2023; 12(10).
PMID: 37408237 PMC: 10217061. DOI: 10.3390/cells12101403.